COVID-19 grants and funding

The subsidy landscape is responding quickly to the COVID-19 virus and the problems this crisis causes world-wide. A lot of new funding opportunities are being released to assist researchers and companies with their Research and Development activities against COVID-19. This overview of all available calls will be updated regularly. Catalyze can help you to find what you need in this rapidly changing subsidy landscape and is available to  assist you in writing successful proposals.

Worldwide grants

MERCK KGaA: Research Grant for pandemic preparedness 

Subsidy: up to  €500,000/year

Deadline: on a daily basis

Project duration: 3 years with the option of extension

Consortium: Globally, scientists in all career stages who are affiliated with any research-based institution, university or company.

Scope: The recent COVID-19 pandemic shows that pandemic preparedness and having the right products and technology to fight infectious diseases with epidemic and pandemic potential is of utmost importance.

Proposals will be considered that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.

Pre-outbreak R&D Preparedness for pandemic disease:

  1. Assessing the priority of pathogens and diseases with epidemic threat
  2. Platform technologies to accelerate the development of vaccines, drugs, diagnostics, vector control tools and delivery systems needed to control emerging health threats
  3. Innovative technologies for better personal protection equipment for infection control

Response during outbreak:

  1. Novel health technologies (e.g. AI, bioelectronics, diagnostics) for early screening of potential infected patients and treatment facilitation.
  2. Fast-track identifying, testing and production of effective drugs and vaccines during outbreak

Visit the website


CEPI: Achieving an unprecedented acceleration of vaccine development and global manufacturing capacity to prevent COVID-19

Subsidy: not specified.

Deadline: open on rolling basis (at least untill 30 June 2020, applications will be reviewed every 2 weeks)

Consortium: open worldwide, to all types of organization: for-profit companies; non-profit organisations; international institutions and foundations; joint R&D ventures; government research organisations; and other vaccine developers. In the consortium a manufactures should be included, and a member with experience in human vaccine development.

Scope: The objective of this Call for Proposals is to support the rapid development of vaccines with a goal of achieving licensure/emergency authorization in 12-18 months or less and to ensure the availability of sufficient doses for wide-spread global deployment as soon as possible in 2021.

This Call will be of potential interest to organizations who have already secured resources for a vaccine candidate for a given COVID-19 target indication or region, and now seek additional support, based on the above principles, to aid expansion of global development plans, support large clinical trials, and/or widen the geographical manufacturing footprint.

Visit the website


NIH: NIAID – Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01, Clinical Trial Not Allowed) – PAR-20-178

Subsidy: no limit

Deadline: Applications will be accepted on a rolling basis, beginning on 30 April 2020.

Consortium: Both US and non-US for profit and non-profit organizations can apply.

Scope: The purpose of this grant is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Examples of research areas are: studies to understand the viral infection, replication and pathogenesis, studies to understand viral transmission, identification and characterization of immunity, development of clinical diagnostic tests and therapeutics (in vitro, ex vivo or animal models), vaccines, and more.

Visit the website



NIH: NIAID- Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21, Clinical Trial Not Allowed) – PAR-20-177

Subsidy: $275,000 (max. $200,000 in one year)

Deadline: Applications will be accepted on a rolling basis, beginning on 30 April 2020

Consortium: Both US and non-US for profit and non-profit organizations can apply.

Scope: The purpose of this grant is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Examples of research areas are: studies to understand the viral infection, replication and pathogenesis, studies to understand viral transmission, identification and characterization of immunity, development of clinical diagnostic tests and therapeutics (in vitro, ex vivo or animal models), vaccines and more.

Visit the website



Pfizer – global medical grants – COVID-19 Competitive Grant Program (educational programs)

Subsidy: $20,000 to $250,000 USD

Deadline: May 22, 2020

Consortium: Global: Only organizations are eligible to receive grants, not individuals or medical practice groups. Eligible groups include: medical, dental, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations; or government agencies.

Scope: The aim is to support educational programs for healthcare providers focused on the recognition, diagnosis, treatment, and overall care management of patients with COVID-19, as well as provide support to hospitals or healthcare systems so that they may evaluate and improve their systems-of-care for COVID-19 patients.

It is NOT in scope for this RFP to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will NOT be considered. It is also NOT in the scope of this RFP for funds to be used to purchase therapeutic agents (prescription or non-prescription), capital equipment, or PPE.

Visit the website


Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

Subsidy: no limit

Deadline: Stage 1: 30 April 2020, 31 July 2020, 31 October 2020. Full proposal on invitation only.

Consortium: All researchers from anywhere in the world. Both for-profit and non-profit organizations are eligible.

Scope: projects must fall under one of the areas of interest.

  • Area of interest #7: emerging diseases diagnostics: diagnostic assay for detection of COVID-19 disease (SARS-CoV-2 infection)
  • Area of interest #8: Influenza and emerging infectious diseases vaccines: COVID-19 vaccine
  • Are of interest #9: influenza and emerging infectious diseases therapeutics: COVID-19 therapeutics
  • Area of interest #17: (NEW) Advanced Manufacturing technologies: The development and demonstration of innovations and enhancements to manufacturing platforms to support the development of necessary medical countermeasures including vaccines and therapeutics in prevention, preparation, and response to COVID-19.

Read more about this call or visit the BARDA website.


Department of Defense CDRMP- Peer Reviewed Medical Research Program for Emerging Viral Diseases and Respiratory Health

This program consists of 3 Award types: Clinical Trial Award, Investigator- Initiated Research Award Technology/Therapeutics Development Award. Each award is described below in more detail with budget, deadline and activities that are funded.

Rules and conditions for every type of Award:

Consortium: All organizations, including international organizations, are eligible to apply.

Scope: projects must specifically address at least one of the following Focus Areas and must be of clear scientific merit and direct relevance to military health:

Emerging Viral Diseases

  • On demand identification, isolation, characterization and manufacturing of antibodies (monoclonal or polyclonal) from peripheral blood mononuclear cells (PBMCs) collected from patients with coronavirus disease 2019 (COVID-19).
  • Development of a wearable sensor that provides real-time diagnostics that can be used as a point of care for emerging viral diseases to predict illness before onset of symptoms. The diagnostic platform should be applicable to COVID-19. Virus-specific markers that can identify viruses at the genus level can be included, with an emphasis on SARS-CoV-2, the virus that causes COVID-19.
  • Surveillance and predictive modelling tools that leverage artificial intelligence approaches to predict outbreaks and epidemics and support strategies for mitigating the threat of COVID-19.
  • Triage of care for COVID-19 patients requiring access to resource-intensive interventions.
  • Research to understand novel molecular and biological mechanisms of COVID-19 health impacts (e.g., microbiome) and identification/validation of biochemical, physiological, or combined biomarkers for evaluating short- and long-term health impacts from COVID-19.
  • Research to determine direct and indirect impacts of COVID-19 on military readiness and unit climate; interpersonal/family dynamics; behavioral and mental health issues such as depression, suicide, anxiety, and loneliness and other key risk factors such as substance abuse and risky health-related behaviors. The aim of such research should be to inform, develop, and test potential behavioral countermeasures (e.g., knowledge and information products, preparedness training, support resources, self-care and team-care recommendations) to mitigate negative impacts and maximize Service member and family readiness/resilience to stressors related to pandemics and disasters.

Respiratory Health

  • Research on the etiology and prevention of acute respiratory distress syndrome (ARDS) caused by host responses to coronaviruses, particularly COVID-19.
  • Development of improved methods for assessing and treating lung injury due to coronaviruses, particularly COVID-19.
  • Novel and/or innovative detection technologies or therapeutics to reduce the incidence and/or severity of ARDS and/or other lung injury secondary to coronaviruses, particularly COVID19.
  • Development of biomarker metrics to associate the long-term health outcomes of virus induced ARDS with degradation of physiological and physical performance.
  • Ventilation and Extracorporeal Life Support approaches and technologies to support lung function or airway management in response to COVID-19 that increase survivability and/or minimize care provider burden or exposure.
  • Pharmacological and biologic interventions for COVID-19 induced complications, including ARDS and related sequelae.
  • Research on the short- and long-term health impacts of COVID-19 diagnosed Service members on readiness, deployability, fitness for duty (e.g., ability to complete the Army Combat Fitness Test), and operationally relevant respiratory challenges such as challenges in fixed-wing aviation, diving, and high-altitude ground operations.
  • Research on the prevention of COVID-19 (and other respiratory pathogens) in aircraft, ships, and submarines, specifically focused on ventilation systems and ease of transport of airborne pathogens (i.e., risk characterizations).

Clinical Trial Award

Subsidy: $6M per project

Deadline: pre-proposal: 8 June 2020                       Full proposal: 22 June 2020

Scope: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first in human, Phase 0), to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. All applications for this Program Announcement must specifically address at least one of the following Focus Areas and must be of clear scientific merit and direct relevance to military health.

Visit the website

Investigator-Initiated Research Award

Subsidy: max. $1.6M

Deadline: pre-proposal: 28 May 2020                      Full proposal: 12 June 2020

Scope: The rationale for a research idea may be derived from a laboratory discovery, population-based studies, a clinician’s first-hand knowledge of patients, or anecdotal data. Applications must include relevant data that support the rationale for the proposed study. These data may be unpublished or from the published literature.

Only for the investigator-initiated research award: the initiative comes from the academia/ non-profit research organizations (main applicant). Companies can be partners.

visit the website

Technology/Therapeutic Development Award

Subsidy: max. $4M

Deadline: pre-proposal: 28 May 2020                      Full proposal: 12 June 2020

Scope: the Technology/Therapeutic Development Award is a product-driven award mechanism intended to provide support for the translation of promising preclinical findings into products for clinical applications in one or more Focus Areas published in this funding opportunity for the Topic Areas of Emerging Viral Diseases and/or Respiratory Health. Products in development should be responsive to the healthcare needs of military Service members, Veterans, and/or beneficiaries. Proof of concept demonstrating the potential utility of the proposed product, or a prototype/ preliminary version of the proposed product, should already be established.

Visit the website



H2020 SC1-PHE-Coronavirus-2020-2A: Repurposing of manufacturing for vital medical supplies and equipment (IA)

Subsidy: €5,000,000- 6,000,000

Funding rate: 70%  (non-profit 100%)

Deadline: 11 June 2020

Consortium: At least three legal entities. Each of the three must be established in a different EU Member State or Horizon 2020 associated country. All three legal entities must be independent of each other.

Scope: Proposals for innovation actions targeted under this topic should address the re-orientation and repurposing of production capacities to meet the urgent needs of our societies for vital medical supplies and equipment. Activities should start at least at TRL 6 and achieve TRL 8 at the end of the project. The scope covers:

  • The repurposing, adaptation and ramp-up of production lines to quickly adjust to new and urgent production needs, notably medical equipment (e.g. personal protective equipment (PPE), ventilators), diagnostic technologies already deployed based on advanced materials and/or biotechnologies, as well as service systems and automated systems of disinfection,
  • Demonstrate flexibility models for the supply chain for the repurposing of production lines and proper risk management in case of disruption of supply chains (or other necessary means for enabling production, such as energy feedstock),
  • Automation technologies that are less dependent on work force present in factories, certification/calibration/accreditation of production lines that have been repurposed or restarted after a shutdown,
  • Qualification of operators/technicians for new/repurposed production lines.

Visit the website


H2020 SC1-PHE-Coronavirus-2020-2B: Medical Technologies, Digital tools and Artificial Intelligence analytics to improve surveillance and care at high Technology Readiness Levels (TRL)  (IA)

Subsidy: €2,000,000- 5,000,000

Funding rate: 70%  (non-profit 100%)

Deadline: 11 June 2020

Consortium: At least three legal entities. Each of the three must be established in a different EU Member State or Horizon 2020 associated country. All three legal entities must be independent of each other.

Scope: The proposed actions could encompass a combination of tools and technologies, such as: microelectronics, micro/nano/cyber-physical systems; bio-functionalized chips and biosensor arrays; bio-photonics; graphene or related materials (GRM); data, AI and robotics; pathogen detection technologies; e-health, telemedicine and digital solutions.

The proposals should address one or more of the following areas:

  • Fast, cost-effective and easily deployable sampling, screening, diagnostic and prognostic systems, including new methods for screening of lungs, using for example AI or advanced photonics solutions, to detect the presence of the pathogen related parameters especially in an early stage of infection;
  • Environmental surveillance (sewage, air, etc.) systems and data analytics as a sentinel for viral (re)emergence and spread in communities, based for example on optical biosensors or genetic detection;
  • Low cost sensors, smart wearable devices and robotics/AI for telemedicine, telepresence and continuous remote monitoring of patient parameters;
  • Protection of healthcare practitioners and the general public improving for example the wetting and filtering properties of fabrics used for face masks; sensors, sterilisation, including robotics and AI solutions, for disinfection and social distancing in environments such as healthcare, public spaces and buildings;
  • Innovative data-driven services and tools combining data assets from various relevant privately held and/or publicly available sources. These could include AI-based solutions exploiting such data and possibly additional sensor-based signals, for diagnostics, prevention, treatment, or rehabilitation.

Visit the website


H2020 SC1-PHE-Coronavirus-2020-2C: Behavioural, social and economic impacts of the outbreak response (RIA)

Subsidy: €4,000,000- 10,000,000

Funding rate: 100%

Deadline: 11 June 2020

Consortium: At least three legal entities. Each of the three must be established in a different EU Member State or Horizon 2020 associated country. All three legal entities must be independent of each other.

Scope: Proposals should focus on lessons learnt: they should i) address how to mitigate social and economic impacts of the outbreak response related to health systems; ii) identify non-intended consequences of epidemic-control decisions; and iii) provide answers to social, including gendered, dynamics of the outbreak and the related public health response. Proposals should analyse the effects and efficiency of these responses (including resilience factors), democratic governance, multi-level cooperation, the critical gaps and the various exit strategies, their underlying methodologies and regional adaptations. Proposals are expected to develop guidelines and best ‘next practices’, and implement interventions to mitigate impacts and boost wellbeing.

Visit the website

H2020 SC1-PHE-Coronavirus-2020-2D: Pan-European COVID-19 cohorts (RIA)

Subsidy: €15,000,000- 20,000,000

Funding rate: 100%

Deadline: 11 June 2020

Consortium: At least three legal entities. Each of the three must be established in a different EU Member State or Horizon 2020 associated country. All three legal entities must be independent of each other.

Scope: Proposals submitted under this expression of interest are expected to establish new and/or build on existing large-scale cohorts to rapidly advance the knowledge on the control of the SARS-CoV-2 infection, develop evidence-based recommendations for effective prevention of the spreading, protection of the population in the coming months/years, and optimized treatment of the COVID-19 patients. The population-based cohorts should also inform on longer-term consequences of COVID-19 on health and well-being of individuals.

Visit the website


H2020 SC1-PHE-Coronavirus-2020-2E: Networking of existing EU and international cohorts of relevance to COVID-19 (CSA)

Subsidy: €2,000,000- 3,000,000

Funding rate: 100%

Deadline: 11 June 2020

Consortium: At least one legal entity established in an EU Member State or Horizon 2020 associated country.

Scope: Proposals under this coordination and support action should support the international networking of existing, mainly longitudinal, cohorts in order to extract jointly agreed standardized data on COVID-19 diagnosed/serotyped and matched non-infected individuals.

This effort should contribute to help in the identification of key factors influencing the susceptibility to infection and clinical manifestation, to assess the optimized therapeutic and clinical management options, and to derive lessons on the health and socio-economic impacts of the pandemic.

They should develop cohort readiness to adapt rapidly to future crisis. Proposals should consider strategies to interact with the COVID-19 cohort(s) that will be funded under this expression of interest and international initiatives on cohorts, as well as liaising with the network of clinical trials on COVID-19.

Visit the website


EUREKA: Solutions for the next human high-impact pandemic

Subsidy:  varies per country (for NL max. €350,000, 25-50% funding rate).

Deadline: 15 July 2020 (national submission deadlines varies).

Project duration: up to 3 years (Projects Result Implementation: Up to 24 months after project completion preference for shorter launches)

Consortium: The consortium should include at least two organisations independent of each other from two of the participating countries. Belgium, Canada, Estonia, Finland, France, Netherlands, South Africa, Spain, Sweden, Turkey.

Scope:  Participants are invited to submit research and innovation project proposals aiming to provide solutions and preparedness for highly contagious human infectious disease pandemics which inflict a high impact on society. The product, process or service must be innovative and there must be a technological risk involved. These can include (but are not limited to):

  • Technologies enabling local resilience or self sufficiency
  • Medical intervention robotics
  • Infection prevention and protection
  • Prevention of antibiotic resistance
  • Sanitation technology
  • Diagnostics and testing
  • Therapeutics, vaccines and medicines
  • Medical intervention robotics
  • Disease-tracking technology
  • Smart technologies for critical production and supply chains under lockdown
  • Education technologies and digital workplace
  • Govtech/Open data and Big Data

Visit the website


AMable: Call for Solution Ideas (COVID-19) 

Subsidy:  €10,000 per challenge for project of 6-12 weeks

Deadline: 1 October 2020

Consortium: An entity that applies for financial support needs to be a natural person or a legally recognised company of any type, registered within the European Union or a country that is linked to the H2020 program. Preference will be given to SMEs and midcaps. Research and technology development organisations are not eligible, nor consortium members.

Scope:  Support activities that propose a realistic solution to a practical challenge. Challenges that society currently sees in coping with the COVID-19 pandemic. The AMable consortium will publish these challenges in so called “challenge sets” on its website. These challenges will be regularly updated.

Challenges from such a challenge set, can include for example: a lack of equipment, helpful tools, replacement parts or parts that enable additional functionality. Overall, such challenges need to be solved when additive manufacturing provides a solution.

The applicants need to provide the following to be selected for support:

  • A solution idea that would solve the selected challenge by additive manufacturing. The proposal needs to sketch the baseline of that idea.
  • A list of tasks that need to be addressed to create the solution and the support that the proposer expects from the AMable consortium.
  • List of the proposer’s expected effort to develop a first prototype of the solution, budget for personnel cost and consumables.

Visit the website


EIT Health: Calls Amended Pandemic COVID-19 to the Innovation Projects

Subsidy: max. €500,000 (for the start-up), total project: max. €3M

Deadline: 27 May 2020 (LOI); 8 July 2020 (full proposal) for programs: Innovation; Campus; Accelerator.

Consortium: SME (located in EU or H2020 associated countries) can apply as external partner together with Core partners from EIT Health consortium. The SME must meet specific requirements.

Scope: Given the recent coronavirus spread and global pandemic of COVID-19, submissions are also welcome that address one or more topics related to the prevention and management of the current, as well as potential future, pandemics:

  • Hinder disease spread and prevention of outbreaks;
  • Optimise screening and diagnosis;
  • Treat people better;
  • Healthcare organisation’s resource management, logistics and supply chains;
  • Data-driven initiatives.

Visit the website



Deutsche Forschungsgemeinschaft (DFG)- Call for Multidisciplinary research into Epidemics and Pandemics in Response to the Outbreak of SARS-CoV-2

Deadline: Letter of intent: 1 July 2020. Full proposal: 1 September 2020

Consortium: Researchers (single applicant or consortium) based at universities, universities of applied sciences, non-university research institutions and healthcare facilities. Applicants should aim to cooperate with international researchers.

Scope: Funding is available for multi-disciplinary projects addressing the prevention, early detection, containment and investigation of the causes, impacts and management of epidemics and pandemics, taking the example of SARS-CoV-2 and other microorganisms and viruses that are pathogenic to humans. This includes for example, the investigation of:

  • The challenges and effects of an epidemic or pandemic and of measures taken for healthcare systems;
  • Psychological, social and cultural factors in the emergence, spread and treatment of epidemics and pandemics and the legal and ethical implications;
  • The impacts on global and regional economic development, production and value creation chains, logistics, transport and communication;
  • Fundamental biological and medical aspects of a pathogen and the associated symptoms, as well as therapeutic methods or preventive measures in combination with one or more of the above topic areas.

Read more about this call or visit the DFG website.



ZonMw: COVID-19 bottom-up project idea focus area 3 Social Dynamics

Subsidy: max. €500,000 per project (for single applications max. €200,000)

Deadline: project idea: 25 May 2020                     full proposal: 29 June 2020

Consortium: Dutch universities, care organisations, UMC’s, non-academic hospitals, patients organisations can apply.

Scope: the focus area 3 focuses on generating new knowledge about social dynamics during and after the corona crisis and measures taken against it. What is the impact of this on the Dutch society? What social and economic problems has it exposed or created? Which restart scenarios can be successful after a shorter or longer period of economic and social disruption? What are the positive effects of the crisis, what can we learn from it? The focus area has 3 themes:

  1. Investigate the effectiveness and impact of measures/ strategies in response to the corona crisis
  2. Research into the resilience of the society
  3. Research on economic resilience.

Visit the website


ZonMw: COVID-19 Science for practice

Subsidy: max. €25,000 (for a project of max 6 months)

Deadline: 25 May 2020

Consortium: Dutch universities, UMC’s, research organizations in collaboration with companies, local authorities, patient organizations etc. can apply.

Scope: Organisations such as care organisations, companies, schools, local authorities, public transport are faced with practical questions and problems as a result of the corona crisis and the measures taken against it. By combining scientific and practical knowledge, solutions can be proposed that help to answer practical questions and facilitate problem within a short time.

Subsidy can be used for scientific expertise, data collection and processing, testing and experimentation of the required services of third parties.

Visit the website



ZonMw – COVID-19 bottom-up aandachtsgebied 1 en 2 projectidee fase

Subsidy: max. €500,000 per project.

Deadline: project idea: 14 May 2020             full proposal: 15 June 2020

Consortium: researcher from Dutch universities, academic and non-academic medical centers/hospitals, hogescholen, research organisations, patients organisations can apply. Collaboration with relevant stakeholders is encouraged.

Scope: the project must fall under one of the research areas:

    1. The aim of focus area 1 is to provide knowledge for the (further) development of (predictive) diagnostics, for tailored-made treatment and for the prevention of COVID-19-related effects/symptoms in the early, acute and recovery phases. This involves urgently needed research into new or existing therapies and their mechanisms of action, as well as gaining insights into, among other things, the microbiome, immunity, predictive parameters and tailor-made treatment.
    2. The aim of focus area 2 is to enable urgent research within the 3 themes directly. Various types of research are possible: evaluation projects, action research, effect studies, stimulation projects, efficiency studies on postponed treatment, development of epidemiological models and inventories.

Visit the website


RVO- Extra corona bridge loan for small Dutch companies

Loan: €10,000- 50,000

Interest rate: max. 4% + one time 2% premium

Duration loan: max. 5 years

Scope: this loan is an extra measurement to support Dutch small companies who need it as a consequence of the corona crisis. The Dutch government makes €750M available to support these companies, and will be guarantee for 95%. This means that the bank will be responsible for the other 5%. Companies can apply for this loan via their bank (Rabobank, ABN AMRO, ING, de Volksbank en Triodos).


Visit the website



(Sweden) FORMAS: Urgent grants 2020 to secure access to data or research materials

Subsidy: Costs corresponding to the urgent need.

Deadline: 31 August 2020

Consortium: Participating researchers must have obtained their doctoral degree. Grants for research projects may only be administered by a Swedish university, college or other Swedish public organisation that meets Formas’ criteria for administrating organisations.

Scope: In view of Covid-19 and the current situation in Sweden and the world, Formas’ Research Council has decided to open its urgent call immediately. Formas wants to provide the opportunity to collect data and research materials of an urgent nature to ensure the future availability of research.

Applications are welcome within all Formas’ areas of responsibility that demonstrate an urgent need to secure future access to data (measurement data, collection of samples, etc.) or other research materials (interviews, participating observations, etc.). Applications from all scientific disciplines are welcome: the humanities, natural sciences, social sciences and technology, as well as for interdisciplinary approaches.

Visit the website


Novo Nordisk Fonden- Societal responses to and Preparedness for Emerging Viral Infections 2020

Subsidy: max. 10M DKK

Deadline: 4 June 2020

Consortium: The main applicant must be a Danish researcher from a Danish research institution. Additionally, 1-3 research groups from research institution should be part of the consortium. Participation of industry, and National or International Health Agencies and is strongly advised.

Scope: The proposed research must be in-depth, but the subject can be cross-disciplinary, and should not be considered limited to any particular research methodology or discipline.

The purpose of this call is to give excellent researchers the possibility, in a collaborative effort, to perform in-depth research addressing the interdisciplinary theme “Societal Responses to and Preparedness for Emerging Viral Infections”, including:

  • Surveillance and early detection of disease. Rapid diagnostics of novel viruses. New technologies to prevent or combat epidemic viral infections.
  • Infectious epidemiology, including methods for epidemic modelling, to predict and understand spread of disease. IT based methods for early detection of epidemics.
  • National preparedness to deal with emerging viral infections, including drafting of policies in advance, procedures for rapid testing and approval of new treatments, technologies, and vaccines.

Visit the website



Switzerland SNSF: National Research Programme (NRP) 78 “Covid-19”

Subsidy: CHF 300,000 – 2,000,000

Deadline: 25 May 2020

Consortium: non-profit research organisations based in Switzerland can apply (the standard SNSF eligibility criteria are met). A maximum of four applicants may submit an application. One applicant may be based outside Switzerland if his/her expertise is essential and generates significant added value, up to two if the overall number of applicants is four.

Scope: This new NRP aims to capitalise and build on existing national research competencies, to channel and bundle them into more extensive projects, and to foster multidisciplinary collaborations and sharing of data and results between scientists, health professionals and health authorities. The goal is to support innovative projects that can achieve results as soon as possible and to submit appropriate recommendations and solutions to combat the current Covid-19 crisis in Switzerland.

The NRP comprises four research modules:

  • Module 1: Basic aspects of Sars-CoV-2 biology, pathogenicity and immunogenicity
  • Module 2: New approaches in Covid-19 epidemiology and disease prevention
  • Module 3: Covid-19 vaccine, drug and diagnostics development
  • Module 4: Clinical Covid-19 research and therapeutic interventions

Note: The projects must start between 1 August and 31 October 2020

Visit the website



France: ANR Recherche-Action Covid-19

Subsidy: max. €150,000

Deadline: 28 October 2020

Consortium: Main applicant: a full-time researcher who is a member of a French organization or research institution or of a company with headquarters located in France.

Scope: This call aims to complement the initial action of Flash COVID-19 and addresses the following five priorities:

  1. Epidemiological studies (i.e. New methods of diagnosing infection and asymptomatic carriage and studies of seroprevalence)
  2. Physiopathogenesis of the disease (i.e. new therapeutics; development of animal and cellular models of the disease; evolution of the immune response, nature and duration of acquired immunity)
  3. Infection prevention and control (i.e. mode of virus transmission and study of human and environmental factors influencing)
  4. Ethics and social dynamics (i.e. research and care ethics and human rights; Communication and crisis management)
  5. Global issues of the Covid-19 epidemic (i.e. understanding of the ecological, environmental and human factors at the origin of the emergence of the pandemic and identification of practices to limit the risks future (including international agreements); macro and micro-economic impact and on trade flows of goods and services (including financial)

Visit the website



France DIM Elict: special call for proposals development of innovative technologies & methods to fight SARS-COV-2

Subsidy: €15,000 of running costs and/or human resources and/or €30,000 of equipment

Deadline: open until the further notice (the end of the crisis)

Consortium: Any research team (laboratories, likely non-profit organizations) from the Ile de France region (The region is made up of eight administrative departments: Paris, Essonne, Hauts-de-Seine, Seine-Saint-Denis, Seine-et-Marne, Val-de-Marne, Val-d’Oise and Yvelines) can apply with a project linked to the infectious agent SARS-CoV-2

Scope: The DIM ELICIT would like to support projects developing innovative technologies and methods regarding the analysis, diagnosis and/or treatment to fight SARS-CoV-2.

The technologies targeted in this call will have to belong to at least one Core technologies and one End-user applications:

Core technologies

  • Microfludics
  • Biophotonic and waves
  • Image analysis and Big Data

End-user applications

  • Single Cell/Single molecule
  • Organ on chips
  • Technologies for in vivo biology
  • High Tech – Low Cost technologies

Note: Projects will have to be written in English. The projects submitted must target the acquisition of knowledge.

Visit the website



UK Research and Innovation (UKRI) – Get funding for ideas that address COVID-19

Subsidy: No limit

Deadline: Open (apply at any time)

Consortium: UK based business at any stage or size. Researchers holding existing UKRI standard grants can apply to switch their funding to address the objectives of this call.

Scope: Proposals are invited for short-term projects addressing and mitigating the health, social, economic, cultural and environmental impacts of the COVID-19 outbreak.

UKRI will support excellent proposals which meet at least one of the following:

  • New research or innovation with a clear impact pathway that has the potential (within the period of the grant) to deliver a significant contribution to the understanding of, and response to, the COVID-19 pandemic and its impacts.
  • Supports the manufacture and/or wide scale adoption of an intervention with significant potential
  • Gathers critical data and resources quickly for future research use

Visit the website


UKRI: COVID-19 Rapid Response Rolling Call

Subsidy: no max

Deadline: 1 April 2021

Consortium: Academic Principal Investigators hosted by a UK institution (eligible for UKRI funding) or SMEs, government arm’s length bodies, and NHS organisations, and equivalent UK authorities are also encouraged to apply.

Scope: The research scope of this call is as below:

  • Virology, Immunity and Pathophysiology;
  • Diagnostics;
  • Epidemiology (Transmission, Disease Susceptibility and Severity, Control and Mitigation);
  • IPC and PPE;
  • Public Health, Media and Communication (Public Health; Media and communication);
  • Clinical Management;
  • Primary, Adjunctive and Supportive Therapies;
  • Vaccines;
  • Health and Care Delivery;
  • Underpinning

Visit the website



SBIR/STTR Phase I Proposals Addressing COVID-19

Subsidy: $150,000 (up to $256,000)

Deadline: project pitch required: 4 June 2020, 3 September 2020, 3 December 2020.

Full proposal upon invitation only.

Consortium: US-based small businesses can apply as single applicant or in a consortium. Additional requirements of SBIR & STTR apply

Scope: Focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis. Areas of research that might be considered include, but are not limited to: artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations.

Note: when awarded a phase I grant, businesses are allowed to apply for a phase II grant (up to $1,000,000) 6-24 months after beginning phase I.

Visit the website


NIH: Rapid Acceleration of Diagnostics (RADx) initiative

Subsidy: no limit (total budget $500M)

Deadline: a rolling basis and will be reviewed within a week of receipt. Progression to ‘ deep dive stage’ upon invitation.

Consortium: US scientists and inventors

Scope: To address the COVID-19 pandemic, this program is anticipated to support the fast track development of new tests with improved technical performance and convenience, such as point-of-care and home devices, as well as innovations that make current lab tests faster, more efficient, and more widely accessible. Focus is on improving analytical or operational performance, improving access and reducing cost of testing.

NIBIB will consider innovations at all stages of readiness from early to late stage and from novel testing strategies to optimization of existing SARS-CoV-2 testing approaches. NIBIB will support the full range of product development including commercialization and product distribution. NIH will supply the needed budget, partnerships and other resources to fully deploy successful tests to the public on the shortest possible timeline.  NIH will negotiate cost sharing with for-profit institutions as appropriate.

Visit the website



CIRM: Special Call for COVID-19 Projects Partnership Opportunities in Support of Discovery, Translational and Clinical Trial Stage Activities.

Subsidy: $750,000 (Clinical trial (CLIN2)); $400,000 (Late stage preclinical (CLIN1)); $350,000 (Translational (TRAN1)); $150,000 (Discovery (DISC2))

Deadline: 7 April 2020 (approximately every two weeks thereafter),

Consortium: US for-profit and non-profit organization, depending on location and location of activities, specific rules apply regarding eligibility and funding

Scope: Given the growing surge of COVID-19 cases in California and throughout the world, CIRM is issuing this special announcement to support promising discovery, preclinical and clinical trial stage projects that could quickly advance treatments to COVID-19 patients in need. CIRM is utilizing its established partnering opportunities across Discovery (DISC2), Translational (TRAN1), and Clinical (CLIN1,CLIN2) stages to provide support for COVID-19 related projects.

Visit the website


National Sciences and Engineering Research Council of Canada (NSREC) – NSERC Alliance COVID-19 grants

Subsidy: max. $50,000

Deadline: 1 June 2020

Consortium: Researchers at a Canadian university with an active peer reviewed grant from NSERC, collaborating with at least 1 private-sector, public-sector or not-for-profit organizations.

Scope: The objectives of the NSERC Alliance COVID-19 grants are to accelerate the flow and exchange of research results and research expertise and support research and analysis activities that address partner organization questions or issues.

Examples of eligible projects include, but are not limited to:

  • Computational modelling and simulation for improved understanding of viral populations and of viral evolution;
  • New technologies relevant to the covid-19 pandemic;
  • Better understanding of viral persistence in the environment;
  • Design and engineering expertise in advanced manufacturing of COVID-19-relevant equipment and supplies.

Read more about this call or visit the NSREC website.



Austrian Research Promotion Agency (FFG)- Emergency call to research covid-19: KLIPHA-COVID19: Promotion of corporate projects and clinical studies

Subsidy: €3M

Deadline: expired

Consortium: Austrian companies of all sizes.

Scope: Research projects and clinical studies designed to investigate the effectiveness of existing drugs in the fight against corona. Research projects dealing with the biology of the virus and its transmission, infection prevention and control, and the research and development of therapeutic methods and new diagnostic approaches can also be submitted.

Visit the website


Luxemburg National Research Fund – COVID-19: Launch of FNR fast-track Call

Subsidy: max. €50,000 (co-funding; short projects); funding for longer-term projects is higher.

Deadline: expired

Consortium: Public institutions performing research in Luxembourg, Non-profit associations, societal impact companies (SIS), and foundations engaged in research in Luxembourg. Collaboration with relevant international partners is encouraged.

Scope: The Luxembourgish research community has created a COVID-19 Task Force in order to coordinate response activities, including the FNR and the major Luxembourgish research institutions.  Projects submitted to this call can cover all research domains and disciplines but must be aligned with the WHO’s Coordinated Global Research Roadmap: 2019 Novel Coronavirus (March 2020 version). Proposals for long-term research projects tackling COVID-19 research questions can also be submitted to the FNR CORE 2020 (deadline 4 May 2020) call or the FNR OPEN 2020 (deadline 4 May 2020) call.

Visit the website


German Federal Ministry of Education and Research- Call for funding to research COVID-19 following the outbreak of SARs-CoV-2.

Subsidy: module 1 and 2: €2M, Module 3: €500,000, Module 4: €50,000

Deadline: expired

Consortium: State and state-recognized universities and non-university research institutions, departmental research institutions, institutions of the public health system and health care providers and commercial companies are eligible to apply.


  • Module 1: Combating COVID-19 through early clinical studies for the application of approved therapeutic approaches to Sars-CoV-2.
  • Module 2: Control of COVID-19 through new therapeutic and diagnostic approaches.
  • Module 3: Research contributing to understanding the virus and its spread
  • Module 4: Support for ongoing research projects on corona viruses.

Read more about this call or visit the website.


EUREKA: Multilateral call for solutions for COVID-19 Echo Period – Life without a vaccine

Subsidy: country specific

Deadline: expired

Project duration: max. 1 year

Consortium: participating countries: Austria, Canada, Denmark, France, The Netherlands, Spain, Turkey. The consortium should include at least two organisations independent of each other from at least two of the participating countries.

Scope: Participants are invited to submit research and innovation project proposals aiming to provide short to medium-term responses to COVID-19 specific needs. These may include (but are not limited to):

  • Infection prevention and protection
  • Sanitation technology
  • Diagnostics and testing
  • Therapeutics, vaccines and medicines
  • Disease-tracking technology, analytical solutions for health systems
  • Smart technology for COVID-19 patients
  • Smart technologies and support systems for critical production and supply chains under lockdown
  • Safe mobility: migration data and trends, regional risk monitoring, protection of isolated and risk groups, safe use of public transports
  • Education technologies and digital workplace.

Note: Product, service or process implementation or market launch should happen no later than 6 months after project completion.

Visit the EUREKA website


Israel Innovation Authority- Call for Proposals for R&D Plans of Industrial Products for the Prevention and Treatment of the COVID-19 (Coronavirus)

Subsidy: support of 30-70% of the approved R&D expenses

Deadline: expired

Consortium: Israelian manufacturing companies

Scope: The aim is to aid with R&D and technological innovation plans of manufacturing plants making industrial products intended for the prevention and treatment of the COVID-19. This could include the development of products, raw materials, innovative technologies and manufacturing processes, practical demonstrations, development of prototypes in the final stages of R&D or developing a scaling process for the transition from experimental production to mass-production.

The proposed plans will accelerate solutions for prevention and treatment of the COVID-19 virus and must be technologically innovative relatively to the company’s capabilities as well as generate value in dealing with the virus.

Visit the website


Science Foundation Ireland, Enterprise Ireland, IDA Ireland: COVID-19 Rapid Response Funding Call

Deadline: expired

Consortium:  Applications from organizations based in Ireland: any Research Performing Organisation (RPO); a client company of one of the following government agencies Enterprise Ireland, IDA Ireland, Údaras Na Gaeltachta or Local Enterprise Office (LEO); or any combination of these is eligible. Applications from other organisations, outside those referenced above, are also welcome (prior to submission contact to confirm eligibility).

Scope: The aim is to incentivise RD&I activities that will impact positively on the current crisis. These activities might include the development of innovative solutions based on new, blended or alternative approaches and methodologies to address immediate national needs. Applications that propose the adaptation or repurposing of existing products, processes and technologies are also strongly encouraged.

Problem areas include, but are not limited to:

  • Contact tracing and role of data analytics;
  • Frontline healthcare (supply of ventilators, use and supply of personal protective equipment and infection prevention and control (IPC) methods etc);
  • Monitoring the impact and effectiveness of control and mitigation measures;
  • Re-purposing of existing technologies, products or processes;
  • Rapid, reliable, diagnostic testing and sampling optimisation;
  • Supporting essential behaviours of self-isolation and social distancing;
  • Mitigation measures relating to the disruption that the crisis is having on Irish society, including impact on essential services and supply chains;
  • Epidemiological and sero-epidemiological studies, including novel approaches to better understand transmission and spread of virus (relevant to humans and animals) and to evaluate the potential impact of control measures.

Visit the website



Spanish Instituto de Salud Carlos III- Urgent request for expressions of interest for research projects on Sars-CoV-2 and disease COVID-19

Subsidy:  total budget available €24M

Deadline: expired

Consortium: Universities, other non-profit and for-profit (private) organisation can apply.

Scope: Proposals must be appropriate to the emergency and, allow immediate implementation and start-up in the National Health System, with concrete, early results applicable to the current situation. These proposals may be based on currently existing activities. The scope of these proposals may be:

  • Techniques for rapid virologic diagnosis of SARS-CoV-2
  • Clinical-biological-molecular characterization of COVID-19 disease, stages, prognostic stratification and complications.
  • Development of innovative therapies, new antiviral, antiseptic and disinfectant molecules against SARS-CoV-2. Antiviral resistance studies. Effectiveness of non-pharmacological, prophylactic and therapeutic interventions.
  • Characterization of the SARS-CoV-2 virus, genetic and antigenic variation, the immunological response and the virus-host interaction.
  • Vaccine development, efficacy and applicability.
  • Epidemiological surveillance of SARS-CoV-2 and molecular epidemiology. Environmental and social factors of the spread. Risk factors and population dynamics of SARS-CoV-2 infection.
  • Socio-economic impact of the disease COVID-19. Use of primary care resources, general hospital resources, and critical care resources.
  • Artificial intelligence and massive analysis of integrated data oriented to the epidemiological control of the disease COVID-19.

Read more about this call or visit the website.



DEPARTMENT OF SCIENCE AND TECHNOLOGY NANO MISSION: Short-term Research Grant special call for Nano Coating COVID-19

Subsidy: max. Rs. 25-30 lakhs (including overhead)

Deadline: expired

Consortium: India: mostly research organizations that their findings can be transferred to the partnering Industry or a Start-up.


  • Antiviral Nano-coatings for materials to be used on appropriate material for producing anti-COVID-19 Triple Layer Medical masks and N-95 respirator or better masks in large quantities;
  • All components of Personal Protective Equipment (PPE) for safeguarding the health of all health care workers against COVID-19 with industrial partners for scaling up production.

Visit the website



Novo Nordisk Fonden- Support for projects seeking to mitigate the health consequences of the coronavirus (Covid-19) epidemic in Denmark

Subsidy: max. 5M DKK

Deadline: expired

Consortium: Applicant from public institutions/authorities or private not-for-profit organizations (e.g. NGOs) in Denmark participating in the fight against the coronavirus epidemic.

Scope: The aim is to mitigate the health consequences of the coronavirus epidemic in Denmark. Projects must be able to be initiated immediately but must be of such a nature that the knowledge gathered in the project is made available and can be utilized in similar situations in the future. Aid can be applied for in 3 areas:

  1. Scientific projects that test new treatments, techniques/technologies or preventative measures that can be used quickly to deal with the health system’s challenges in the current situation. Who can apply? Researchers in hospitals, professional colleges and universities.
  2. Informational measures that can improve communication with citizens and knowledge of the health management of the crisis. Who can apply? Authorities and partners.
  3. Social measures to meet the special health needs of vulnerable groups in connection with the crisis. Who can apply? Authorities, NGOs and other not-for-profit organizations.

Visit the website


Nordic Trial Alliance Invites Proposals for Nordic COVID-19 Activities

Subsidy: max. 500,000 NOK

Deadline: expired

Consortium: Participants of at least 3 different Nordic (Norway, Sweden, Finland, Denmark, Iceland) research performing organisations, public sector, patient organisations or other relevant organisations are eligible to apply. Companies are not eligible to receive funding but can take part on their own costs.

Scope: Due to the ongoing COVID-19 pandemic, there is a huge need for new knowledge related to the SARS-CoV-2 virus infection in order to develop vaccines and treatments.

A proposal could for example include (one or several) activities related to:

  • Knowledge transfer
  • Infrastructure establishment
  • Nordic coordination of national initiatives incl. Trials
  • Planning of joint Nordic initiatives
  • Data sharing and interoperability
  • Establishing networks
  • Monitoring
  • Preparedness for future pandemics

Visit the website


ACADEMY OF FINLAND: Call for applications: special funding for research on COVID-19 epidemic and the mitigation of its effects

Subsidy: up to €200,000 (per sub-application)

Deadline: expired

Consortium: Finnish research organisations (universities, higher education institution, research institutes and other research organisations) that have Academy-funded research relevant to the objectives of this call.

Scope: The objective of the Academy of Finland’s special funding for research on the COVID-19 epidemic is to support and accelerate research into the current coronavirus epidemic and the mitigation of its effects and to support the utilisation of the research in society. The aim is to quickly redirect research already underway to support the fight against the COVID-19 epidemic and reduce its consequences.

Visit the website


ZonMw/NWO funding for research to COVID-19 program will open soon!

Subsidy: available for this program is €27M. This new program will focus on different types of research (from fundamental research to action research). Both for short-term and long-term solutions. The program will focus on the following 3 research pillars:

  • Predictive diagnostics and treatment
  • Care and prevention, including transmission
  • Social consequences of the corona crisis and measures against it.

Deadline: expired

Scope: ZonMw will make the subsidies available for each focus area in 3 ways:

  1. Fast track method: subsidies are available for problems and questions that needs to be solved quickly to combat this pandemic. Applications for this procedure will be submitted by invitation as soon as possible.
  2. Thematic bottom-up rounds for research proposals
  3. Policy and practical impulses aimed at small projects and studies. This is aimed at quickly and briefly addressing concrete policy questions and providing practical impulses.

More information about this call (in Dutch)


FNRS: SPECIAL CALL CORONAVIRUS (Crédits Urgents de Recherche)

Subsidy: varies per project (not specified); Teams that have already started research on the coronavirus or are about to do so can submit a claim (limited to €60,000) for costs incurred for the period 1 April – 31 August 2020.

Deadline: expired

Consortium: Belgium Wallonië: The Promoter must be: a Qualified Researcher, Senior Research Fellow or Research Director of the F.R.S.-FNRS or an academic or a scientist appointed on a permanent or probationary basis within one of the 6 FWB universities. The project may be carried out in collaboration or within a university hospital provided that the promoter meets the eligibility conditions.

Scope: A better understanding of the current Coronavirus epidemic requires urgent scientific research. As a reference agency for research funding, the FNRS has the responsibility to respond and release funds to organize calls to mobilize the FWB’s scientific communities and help them contribute to the growing international efforts. The following themes, included in the priorities set by the WHO, are eligible:

  • Epidemiological and translational studies;
  • Physiopathogenesis of the disease (virus-host interactions and immune response);
  • Infection prevention and control measures in the health care setting (including the best ways to protect health workers) and in community settings;
  • Projects aiming at the development of tests in clinical biology/screening are also eligible.

Visit the website


EIT Health- Headstart covid-19 solutions

Subsidy: €50,000

Deadline: expired

Consortium: open for European SMEs, spin-offs and start-ups.

Scope: the aim is to support healthcare start-ups with valuable solutions that can enable the community and health systems to fill in the gap until COVID-19 vaccines are ready. Product/projects must be at least at TRL8. Targeted topics/technologies (only digital solutions):

  • AI driven mHealth
  • Digital Health wearables, devices and sensors
  • Diagnose
  • Mental Health
  • Epidemiology
  • Solutions to support current crisis situations at hospitals (e.g. stock management, patients journey solutions).

The following will not be considered: new tests, drug development, new ventilators equipment.

Visit the website


EDCTP- Mobilisation of funding for COVID-19 research in sub-Saharan Africa

Subsidy: max. €500,000 per project

Deadline: expired

Consortium:  at least 3 independent legal entities, of which 2 in Participating States and 1 in a Sub-Saharan African country.

Scope: Support research activities in sub-Saharan Africa to manage and/or prevent the spread of the current COVID-19 outbreak. At least 1 of the following research gaps should eb addressed:

  • Understanding of the natural history of infection to better define the period of infectiousness and transmissibility; improve surveillance capabilities.
  • Promote the development, adaptation, evaluation, and implementation of point-of-care diagnostic tests.
  • Support standardised, best evidence-based approaches for clinical management and better health outcomes for patients by contributing to the implementation of randomised, controlled trials for diagnostics and therapeutics as promising agents emerge, taking usability, including multi-centre/country trials and access in resource-constrained settings, into account.
  • Validation and adaptation of existing serological tests, including those that have been developed by commercial entities, and establishment of biobanks and serum panels of well characterised COVID-19 sera to support such efforts.

Visit the website


PRACE support to mitigate impact of COVID-19 – Fast Track Call for Proposals pandemic

Subsidy: about 30 million to 50 million core hours (PRACE facilitates its computing resources (supercomputers)).

Deadline: expired

Consortium:  Researchers from academia, from research institutes, and from commercial organisations (industry) based in Europe are eligible to apply.

Scope: PRACE is welcoming project proposals requesting computing resources to contribute to the mitigation of the impact of the COVID-19 pandemic. This applies, without being exhaustive, to the following topics:

  • Biomolecular research to understand the mechanisms of the virus infection
  • Bioinformatics research to understand mutations, evolution, etc.
  • Bio-simulations to develop therapeutics and/or vaccines
  • Epidemiologic analysis to understand and forecast the spread of the disease
  • Other analyses to understand and mitigate the impact of the pandemic

Read more about this call or visit the PRACE website.


The Amazon Web Services Diagnostic Development Initiative (DDI)

Subsidy: $20,000,000 (total budget). Funding will be provided through a combination of AWS in-kind credits and technical support to assist research teams in harnessing the full potential of the cloud to tackle this challenge.


Consortium:  Open to accredited research institutions, research consortia, and private entities that are AWS customers. Entities that are using AWS to support research-oriented workloads for the development of point-of-care diagnostic and other diagnostic techniques.Scope: Innovation in rapid and accurate patient testing for COVID-19, and other diagnostic solutions to mitigate future outbreaks. Accurate testing and diagnosis at point-of-care or regional locations for patients with COVID-19 is critical to early intervention and treatment. AWS is offering technical support and providing AWS promotional credits to support the use of AWS services to advance diagnostic research for selected institutions and companies.

Read more about this call or visit the website.


British Society for Antimicrobial Chemotherapy (BSAC)

Subsidy: £25,000

Deadline: expired

Consortium: Applications are open worldwide to all organizations

Scope: the aim is to support researchers in better understanding and addressing COVID-19 outbreak.

Visit the website


Medical CBRN Defense Consortium (MCDC) Other Transaction Agreement (OTA) Request for Information (RFI) – CoV Pandemic Response

Subsidy: no limit (This request is Market Research to determine the capability of the industrial base to respond to the 2019-nCoV pandemic. At this time, funding has not been identified for any prototype projects under this request).

Deadline: expired

Consortium:  Submission is open to all entities of the US Defense Industrial Base, not just MCDC members.  Should a non-MCDC member be selected for award, that entity would be required to join the MCDC prior to award execution. Foreign firms with no US-based affiliate are also eligible.

Scope:  The focus is on the following areas:

  • Diagnostics/Monitoring: Medical diagnostic devices, with specific emphasis on Point-of-Care diagnostics (e.g. CLIA waived), under development and capable of diagnosing 2019- SARS-CoV-2, within 1-4 months
  • Surveillance: Surveillance methods and associated devices for 2019-SARS-CoV-2 screening.
  • Information systems and technology the US Government can use in a handheld Point-of-Care device to collect, screen, collate, report, and monitor disease infection and pandemic spread on a micro and macro level.
  • Therapeutics: Drugs and/or drug/device combinations, or platforms currently under development demonstrating efficacy in post-exposure, pre- and post-symptomatic studies for any CoV strain, and capable of achieving EUA from the FDA within the next 3 months for this ongoing SARS-CoV-2 pandemic.
  • Prophylactics: Drugs or vaccines currently under development demonstrating pre-exposure in vivo efficacy or in vitro activity against any or all strains of CoV. Antibody technology, accelerating the discovery, development, manufacturing and prediction of success for these technologies can be considered.
  • Clinical Trials: Opportunities to expeditiously conduct clinical trials for any technology that will require evaluation for FDA approval, will be considered.

Read more about this call or visit the MCDC website.


The Lundbeck foundation- Coronavirus research

Subsidy: max. 5M DKK

Deadline: expired

Consortium: Applicants must be affiliated with Danish universities or hospitals and with local authorities, patient associations, think-tanks or similar organisations.

Scope: The foundation aims to provide funding for biomedical science research activities with the potential to mitigate the impact of the COVID-19 pandemic. The funding is available for research-based projects with a patient focus. Projects must have the potential for direct impact in this acute situation and therefore be able to be initiated without delay.

Visit the website


RVO- Stimulering E-Health Thuis (SET) Coronavirus

Subsidy: €50,000

Deadline: expired

Consortium: A care provider (formal or informal) to clients living at home or aimed at returning home. This includes, for example, health organizations, district nursing, GGZ providers and hospitals.

Scope: The care of vulnerable elderly people living at home or people with a chronic illness or disability is under pressure due to the COVID-19 and the measures to prevent the virus from spreading. Healthcare organizations therefore quickly need more technological options to provide remote care. The proposed activities contribute to the continuity of remote care for clients living at home during the corona crisis, or the activities are aimed at removing the obstacles resulting from this crisis.

Read more about this call or visit the RVO website.


ZonMw extra funding for creative solutions COVID-19

Subsidy: Start impulse max. €7,5000 and Project impulse: €7,500-15,000

Deadline:  expired

Consortium: all Dutch innovators can apply

Scope: The aim is to fund creative solutions to the challenges regarding COVID-19. On the one hand, this concerns practical technological solutions in (hospital) care, such as medical devices. On the other hand, it is about innovative ideas to help vulnerable groups and their care and care providers in providing the right care and support. This concerns solutions that fall outside regular care and welfare activities. There are two financial impulses:

  1. Start Impulse: intended for developing and potential piloting of your project
  2. Project Impulse: important condition for this is that the creative solution meets the needs of the target group.

Visit the website



Catalyze Figure Ovals Lightgray

A must-have if you’re interested in getting your business to the next level